Skip to menu Skip to content Skip to footer

2014

Conference Publication

Combined in Vivo and in Vitro Analyses Identify the Caspase-1/trpm2 Axis as a Contributor to Neutrophil-Driven Airway Inflammation in Cystic Fibrosis

Forrest, O., Ingersoll, S., Robertson, A. A., Preininger, M., Laval, J., Brown, M., O'Neill, L., Cooper, M. A., Tangpricha, V and Tirouvanziam, R. (2014). Combined in Vivo and in Vitro Analyses Identify the Caspase-1/trpm2 Axis as a Contributor to Neutrophil-Driven Airway Inflammation in Cystic Fibrosis. The 28th Annual North American Cystic Fibrosis Conference, Atlanta, GA United States, 9-11 October 2014. Hoboken, NJ United States: John Wiley and Sons. doi: 10.1002/ppul.23108

Combined in Vivo and in Vitro Analyses Identify the Caspase-1/trpm2 Axis as a Contributor to Neutrophil-Driven Airway Inflammation in Cystic Fibrosis

2014

Conference Publication

MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases

Coll, Rebecca C., Robertson, Avril A. B., Chae, Jae Jin, Higgins, Sarah C., Dungan, Lara S., Munoz-Planillo, Raul, Monks, Brian G., Croker, Daniel E., Sutton, Caroline E., Stutz, Andrea, Nunez, Gabriel, Latz, Eicke, Kastner, Daniel L., Mills, Kingston H. G., Masters, Seth L., Schroder, Kate, Cooper, Matt A. and O'Neill, Luke A. J. (2014). MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases. 2nd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Melbourne Australia, Oct 26-29, 2014. London United Kingdom: Academic Press. doi: 10.1016/j.cyto.2014.07.037

MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases

2014

Conference Publication

Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia

Dempsey, Colin, Coll, Rebecca, Robertson, Avril, Cooper, Matthew, O'Neill, Luke and Lynch, Marina (2014). Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia. 12th International Congress of Neuroimmunology (ISNI), Mainz Germany, 9-13 November 2014. AMSTERDAM: ELSEVIER SCIENCE BV. doi: 10.1016/j.jneuroim.2014.08.393

Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia

2014

Conference Publication

What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH

Gan, L. T., Van Rooyen, D. M., Cooper, M., Robertson, A., Masters, S., Teoh, N. and Farrell, G. (2014). What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH. Australian Gastroenterology Week, Broadbeach, QLD, Australia, 22-24 october 2014. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12736

What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH

2014

Conference Publication

Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells

Arbore, Giuseppina, Fara, Antonella F., Coll, Rebecca, Robertson, Avril, Cooper, Matthew, O'Neill, Luke A. J., Lavender, Paul, Cope, Andrew, Lachmann, Helen J. and Kemper, Claudia (2014). Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells. 25th International Complement Workshop, Rio de Janeiro, Brazil, 14-18 September 2014. Kidlington, Oxford, United Kingdom: Pergamon Press. doi: 10.1016/j.molimm.2014.07.010

Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells

2014

Conference Publication

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

McGarry, Trudy, Connolly, Mary, Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., O'Neill, Luke A., Veale, Douglas J. and Fearon, Ursula (2014). Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis. 78th Annual Meeting of the American College of Rheumatology/49th Annual Meeting of the Association of Rheumatology Health Professionals, Boston, MA United States, 14-19 November 2014. Hoboken, NJ United States: John Wiley and Sons.

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

2007

Conference Publication

The synthesis of isotopically labelled glucosinolates for analysis and metabolic studies

Botting, Nigel P., Robertson, Avril A. B. and Morrison, John J. (2007). The synthesis of isotopically labelled glucosinolates for analysis and metabolic studies. Ninth International Symposium on the Synthesis and Applications of Isotopically Labelled Compounds, Edinburgh, Scotland, United Kingdom, 16–20 July 2006. Bognor Regis, West Sussex, United Kingdom: John Wiley & Sons. doi: 10.1002/jlcr.1225

The synthesis of isotopically labelled glucosinolates for analysis and metabolic studies